The goal of this clinical trial to test the effect of periimplant soft tissue phenotype in the participants with implant placed and at least 1 year after implant loading. The main questions it aims to answer are: 1. Is keratinized mucosal thickness (KMT) important in early marginal bone loss and peri implant health? 2. Is keratinized gingival width (KGW) important in early marginal bone loss and and peri implant health? The researchers plan to include 80 implants in the study. These 80 implants will be divided into 2 groups in 2 different ways according to their KMT and KGW on their buccal surfaces: KMT ≥2 mm are included in the adequate KMT, and those with KMT\<2 mm are in the insufficient KMT group. Those with KGW≥2 mm are adequate KGW, those with KGW\<2 mm are adequate KGW. The researchers will assess marginal bone loss around the implant using radiographs and collect peri-implant crevicular fluid (PICF) using paper strips. Another researchers will measure the Receptor Activator Of Nuclear Factor-Kappa B Ligand (RANKL), Osteoprotegerin (OPG), Tumor Necrosis Factor Alpha (TNF-α), MicroRNA-223 (MiRNA-223), MicroRNA-27a (MiRNA-27a) levels in the collected PICF. They will compare radiographic bone loss and biomarker levels in groups.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Comparison of mean Receptor Activator Of Nuclear Factor-Kappa B Ligand (RANKL) level between peri-implant health and peri-implant mucositis groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.
Comparison of mean Osteoprotegerin (OPG) level between peri-implant health and peri-implant mucositis groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.
Comparison of mean Tumor Necrosis Factor Alpha (TNF-α) level between peri-implant health and peri-implant mucositis groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.
Comparison of mean MicroRNA-223 level between peri-implant health and peri-implant mucositis groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.
Comparison of mean MicroRNA-27a level between peri-implant health and peri-implant mucositis groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.
Comparison of alveolar bone loss between adequate Keratinized mucosal thickness (KMT) and inadequate KMT groups
Timeframe: It will be done at the start of the study, immediately after the control radiograph is taken.
Comparison of alveolar bone loss between between adequate keratinized gingival width (KGW) and inadequate KGW groups
Timeframe: It will be done at the start of the study, immediately after the control radiograph is taken.
Comparison of mean Receptor Activator Of Nuclear Factor-Kappa B Ligand (RANKL) level between adequate KMT and inadequate KMT groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.
Comparison of mean Receptor Activator Of Nuclear Factor-Kappa B Ligand (RANKL) level between adequate KGW and inadequate KGW groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.
Comparison of mean Osteoprotegerin (OPG) level between adequate Keratinized mucosal thickness (KMT) and inadequate KMT groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.
Comparison of mean Osteoprotegerin (OPG) level between between adequate keratinized gingival width (KGW) and inadequate KGW groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.
Comparison of mean Tumor Necrosis Factor Alpha (TNF-α) level between adequate Keratinized mucosal thickness (KMT) and inadequate KMT groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.
Comparison of mean Tumor Necrosis Factor Alpha (TNF-α) level between between adequate keratinized gingival width (KGW) and inadequate KGW groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.
Comparison of mean MicroRNA-223 level between adequate Keratinized mucosal thickness (KMT) and inadequate KMT groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.
Comparison of mean MicroRNA-223 level between between adequate keratinized gingival width (KGW) and inadequate KGW groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.
Comparison of mean MicroRNA-27a level between adequate Keratinized mucosal thickness (KMT) and inadequate KMT groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.
Comparison of mean MicroRNA-27a level between between adequate keratinized gingival width (KGW) and inadequate KGW groups
Timeframe: this will be done at the beginning of the study, after samples have been collected from all implants in the study.